Neuroprotective therapy of glaucoma

Vlasova A.S.; Petrov S.A.; Renzyak E.V.; Malishevskaya T.N.

doi:https://doi.org/10.17116/oftalma202514101183

Close metadata

Recommended articles:

The role of the structure of the lamina cribrosa in the diagnosis and treatment of glaucoma. Structural and circulatory changes in the lamina cribrosa with aging and elevated intraocular pressure. Russian Annals of Ophthalmology. 2025;(1):76-82

Predictive modeling of glaucomatous optic neuropathy progression rate in patients with newly diagnosed early primary open-angle glaucoma. Russian Annals of Ophthalmology. 2025;(2):22-29

Modern approaches to combined surgery for cataract and primary open-angle glaucoma. Russian Annals of Ophthalmology. 2025;(3):92-99

The effect of Mexidol on the level of neurogenesis markers in acute cerebrovascular accident in the experiment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):107-112

The main mechanisms of development of cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):13-18

The known and new ideas about the mechanism of action and the spectrum of effects of Mexidol. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):22-33

Therapeutic potential of quercetin and its derivatives against COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):44-50

Targets of rational neuroprotection in the therapy of chronic cerebral ischemia and the possibilities of achieving them. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):96-101

Results of the international multicenter randomized, double-blind, placebo-controlled clinical trial for the evaluation of the efficacy and safety of the sequential therapy with ethylmethylhydroxypyridine succinate in patients in the acute and early recovery periods of ischemic stroke (MIR). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):40-53

Abstract:

Glaucoma is a chronic multifactorial neurodegenerative disease; the most studied local risk factors for glaucoma progression are elevated intraocular pressure (IOP) and its diurnal fluctuations. However, normalization of IOP does not always guarantee stabilization of the glaucomatous process. This article reviews data from international and Russian studies on the pathophysiological mechanisms underlying the development and progression of glaucomatous optic neuropathy, and discusses current approaches to its therapeutic management.

Keywords:

primary open-angle glaucoma

glaucoma optic neuropathy

neuroprotection

antioxidants

ethylmethylhydroxypyridine succinate

Authors:

Vlasova A.S.

West Siberian Institute of Postgraduate Medical Education

ORCID: 0000-0002-6835-3393

Petrov S.A.

West Siberian Institute of Postgraduate Medical Education;
Tyumen Scientific Center of the Siberian Branch of the Russian Academy of Sciences

SPIN RSCI: 8382-8583
ORCID: 0000-0002-1566-2299

Renzyak E.V.

West Siberian Institute of Postgraduate Medical Education;
District Clinical Hospital of the Khanty-Mansiysk Autonomous Okrug — Yugra

ORCID: 0009-0007-2258-2207

Malishevskaya T.N.

Helmholtz National Medical Research Center of Eye Diseases

ORCID: 0000-0003-3679-8619

Received:

13.12.2024

Accepted:

28.12.2024

Close metadata

References:

European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition. Br J Ophthalmol. 2021;105(1):1-169. https://doi.org/10.1136/bjophthalmol-2021-egsguidelines
Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262-267. https://doi.org/10.1136/bjo.2005.08122
Jonas JB, Aung T, Bourne RR, et al. Glaucoma. Lancet. 2017;390(10108): 2183-2193. https://doi.org/10.1016/S0140-6736(17)31469-1
World report on vision. World Health Organization. 2019. Accessed 10.12.2024. https://cdn.who.int/media/docs/default-source/blindness-and-visual-impairment/9789241516570-eng.pdf?sfvrsn=dd15adbb_3
Sotemehin AE, Ramulu PY. Measuring Disability in Glaucoma. J Glaucoma. 2018;27(11):939-949. https://doi.org/10.1097/IJG.0000000000001068
Resnikoff S, Pascolini D, Etya’ale D, et al. Global data on visual impairment in the year 2002. Bull. Wld Hlth Org. 2004;(82):844-851.
Guy AH, Wiggs JL, Turalba A, et al. Translating the Low Translaminar Cribrosa Pressure Gradient Hypothesis into the Clinical Care of Glaucoma. Semin Ophthalmol. 2016;31(1-2):131-139. https://doi.org/10.3109/08820538.2015.1114855
Mallick J, Devi L, Malik PK et al. Update on Normal Tension Glaucoma. J Ophthalmic Vis Res. 2016;11(2):204-208. https://doi.org/0.4103/2008-322X.183914
Mi XS, Yuan TF, So KF. The current research status of normal tension glaucoma. Clin Interv Aging. 2014;16(9):1563-1571. https://doi.org/10.2147/CIA.S67263
Bayer AU, Keller ON, Ferrari F, et al. Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer’s disease and Parkinson’s disease. Am J Ophthalmol. 2002;1:135-137. https://doi.org/10.1016/s0002-9394(01)01196-5
Gupta N, Ang LC, Noel de Tilly L, et al. Human glaucoma and neural degeneration in intracranial optic nerve, lateral geniculate nucleus and visual cortex. Br J Ohthalmol. 2006;90:674-678. https://doi.org/10.1136/bjo.2005.086769
Alekseev VN, Gazizova IR. Neurodegenerative changes in patients with primary open-angle glaucoma. Prakticheskaja medicina. 2012;(4):154-156 (In Russ.).
Rombaut A, Brautaset R, Williams PA, et al. Glial metabolic alterations during glaucoma pathogenesis. Front Ophthalmol (Lausanne). 2023;28(3):1290465. https://doi.org/10.3389/fopht.2023.1290465
Amato R, Cammalleri M, Melecchi A, et al. Natural History of Glaucoma Progression in the DBA/2J Model: Early Contribution of Müller Cell Gliosis. Cells. 2023;12(9):1272. https://doi.org/10.3390/cells12091272
Jassim AH, Nsiah NY, Inman DM. Ocular Hypertension Results in Hypoxia within Glia and Neurons throughout the Visual Projection. Antioxid (Basel). 2022;11:888. https://doi.org/10.3390/antiox11050888
Gazizova IR. Correction of mitochondrial dysfunction as the basis of neuroprotection in glaucoma. Oftal’mologicheskie vedomosti. 2011;(4):64-69 (In Russ.).
Gazizova IR, Mazunin IO, Malishevskaja TN, et al. Mitochondrial DNA as a factor in the development of glaucoma optic neuropathy. Oftal’mologija. 2019;16(4):479-486 (In Russ.). https://doi.org/10.18008/1816-5095-2019-4-479-48.
Levin LA. Direct and indirect approaches to neuroprotective therapy of glaucomatous optic neuropathy. Surv Ophthalmol. 1999;43(1):98-101. https://doi.org/10.1016/s0039-6257(99)00027-2
Teplov DB. Molecular Biology of Neurodegenerative Diseases Visions for the Future-Part B. Academic Press; 2021.
Egorov EA, Brezhnev AJu, Egorov AE. Neuroprotection in glaucoma: current opportunities and prospects. Klinicheskaja oftal’mologija. 2014;(2): 108-112 (In Russ.).
Pervichnaja otkrytougol’naja glaukoma. Nacional’noe rukovodstvo. Eds Egorova EA, Kuroedova AV. Moscow: GEOTAR-Media; 2023 (In Russ.).
Kurysheva NI. Neiroprotektsiya i neiroregeneratsiya: perspektivy v lechenii glaukomy: monografiya. Moscow: Avtorskii tirazh; 2013 (In Russ.).
Usova LA, Harchenko LN, Chencova OB. Medikamentoznoe lechenie pervichnoj glaukomy: uchebnoe posobie. Moscow: MONIKI; 2014 (In Russ.).
Bezdetko PA. Neuroprotective treatment of glaucoma. Oftal’mologija — nauka — praktika. 2014;17:26-27 (In Russ.).
Kurysheva NI. Secondary neuroprotection in glaucoma. Medicinskij sovet. 2008;(3-4):76-77 (In Russ.).
Osborne NN. Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta Ophthalmol. 2009;87(4):450-454. https://doi.org/10.1111/j.1755-3768.2008.01459.x.
Veselovskaja ZF, Veselovskaja N.N. Primary neuroprotection in glaucoma. Klinicheskaja oftal’mologija. 2011;(4):131-132 (In Russ.).
Netland PA, Chaturvedi N, Dreyer EB. Calcium channel blockers in the management of low-tension and open-angle glaucoma. Am J Ophthalmol. 1993;115(5):608-613. https://doi.org/10.1016/s0002-9394(14)71458-8
Kittazawa Y, Shirai H, Go FJ. The effect of Ca2+ antagonist on visual field in low-tension glaucoma. Graefes Arch Clin Exp Ophthalmol. 1989;227(5): 408-412. https://doi.org/10.1007/BF02172889
Choi SH, Kim KY, Perkins GA, et al. AIBP protects retinal ganglion cells against neuroinflammation and mitochondrial dysfunction in glaucomatous neurodegeneration. Redox Biol. 2020;37:101703. https://doi.org/10.1016/j.redox.2020.101703
Osborne NN, Nunez-Alvarez C, Joglar B, et al. Glaucoma: focus on mitochondria in relation to pathogenesis and neuroprotection. Eur. Pharmacol. 2016;787:127-133. https://doi.org/10.1016/j.ejphar.2016.04.032
Irshad M, Chaudhuri PS. Oxidant-antioxidant system: role and significance in human body. Indian J Exp Biol. 2002;40(11):1233-1239.
Korshunova AB, Prosvirkina IA. Prospects for the use of mexidol in ischemic and metabolic disorders. Bjulleten’ jeksperimental’noj biologii i mediciny. 2012;(1):257-326 (In Russ.).
Shchul’kin AV. Modern ideas about the antihypoxic and antioxidant effects of mexidol. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2018;(12):87-93 (In Russ.). https://doi.org/10.17116/jnevro201811812287
Shchul’kin AV. Effect of mexidol on the development of the phenomenon of the neuronal excitotoxicity in vitro. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2012;112(2):35-39 (In Russ.).
Movsisyan AB, Oganezova ZhG, Egorov EA. Use and outcomes of antioxidant therapy in ophthalmic practice. Russian Annals of Ophthalmology=Vestnik oftal’mologii. 2022;138(5):126-132 (In Russ.). https://doi.org/10.17116/oftalma2022138051126
Stakhovskaya LV, Shamalov NA, Khasanova DR, et al. Results of a randomized, double-blind, multicenter, placebo-controlled, parallel group study of the effectiveness and safety of Mexidol during long-term sequential therapy in patients in the acute and early recovery periods of hemispheric ischemic stroke (EPICA). Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2017;117(3-2):55-65 (In Russ.). https://doi.org/10.17116/jnevro20171173255-65
Fedin AI, Zakharov VV, Tanashyan MM, et al. Results of an international multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO). Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2021;121(11):7-16 (In Russ.). https://doi.org/10.17116/jnevro20211211117
Bratko VI. Combined treatment of ophthalmopathology with the use of Mexidol. Bjulleten’ jeksperimental’noj biologii i mediciny. 2012;(1):232-236 (In Russ.).
Egorov EA, Obruch BV, Oleinik AI, et al. The use of the drug Mexidol in patients with dystrophic diseases of the posterior segment of the eye. Klinicheskaya oftal’mologiya. 2009;10(4):145-148 (In Russ.).
Egorov EA, Davydova NG, Romanenko IA, et al. Mexidol in complex treatment of glaucoma. Klinicheskaya oftal’mologiya. 2011;12(3):107-111 (In Russ.).
Egorov EA, Gvetadze AA, Davydova NG. Antioxidant agents in neuroprotection treatment of glaucoma. Russian Annals of Ophthalmology=Vestnik oftal’mologii. 2013;129(2):67-69 (In Russ.).
Bolatbekova AN, Kopbaeva DE, Arinova AI, et al. Evaluation of the effectiveness of Mexidol in the complex treatment of glaucoma neuropathy. Gigiena truda i medicinskaja jekologija. 2015;2(47):67-77 (In Russ.).
Volchegorskij IA, Tur EV, Soljannikova OV, et al. The effect of a water-soluble antioxidant drug (mexidol) on the sensitivity of the optic nerve and the rate of blood flow in the arteries of the eyeball and orbit in patients with primary open-angle glaucoma. Russian Annals of Ophthalmology=Vestnik oftal’mologii. 2012;(4):35-37 (In Russ.).
Malyshev VE, Sal’nikova OI. The experience of using the drug “Mexidol” in the complex outpatient treatment of patients with eye diseases of degenerative-dystrophic origin. Bjulleten’ eksperimental’noy biologii i meditsiny. 2006;(1):55-57 (In Russ.).
Dorofeev DA. The use of antioxidant therapy in the complex treatment of primary open-angle glaucoma. In: III Scientific and Practical Olympiad “Mexidol: 20 years in clinical practice”. Prilozhenie k zhurnalu “Terapiya”. Moscow: Bionika Media; 2019 (In Russ.).
Afonina EA, Levko MA, Chekurova LV, et al. Our experience of using mexidol in the complex treatment of patients with primary open-angle glaucoma. In: Russian glaucoma school. Conference “Glaucoma: theory and practice”. St. Petersburg: Chelovek i ego zdorov’e; 2013;8:33-37 (In Russ.).
Loskutov IA, Andrjuhina OM, Kovrizhkina AA. The use of Mexidol in the treatment of primary open-angle glaucoma. Effektivnaya farmakoterapiya. 2022;18(11):52-56 (In Russ.).
Leonova ES, Poljakov SV, Pozdnjakova MA, et al. The experience of neuroprotective therapy of primary open-angle glaucoma based on the use of various forms of Mexidol. Russian Annals of Ophthalmology=Vestnik oftal’mologii. 2015;(6):90-93 (In Russ.).
Malishevskaja TN, Filippova JuE. The effect of antioxidant therapy on some pathogenetic factors of primary open-angle glaucoma. Russian Annals of Ophthalmology=Vestnik oftal’mologii. 2023;139(4):35-43 (In Russ.). https://doi.org/10.17116/oftalma202313904135
Vlasova AS, Malishevskaja TN, Petrov SA, et al. The importance of mitochondrial dysfunction in the stabilization of the glaucoma process. Russian Annals of Ophthalmology=Vestnik oftal’mologii. 2024;140(4):48-57 (In Russ.). https://doi.org/10.17116/oftalma202414004148
Klinicheskie rekomendacii «Glaukoma pervichnaja otkrytougol’naja». 2024. Accessed 10.12.2024 (In Russ.). https://cr.minzdrav.gov.ru/preview-cr/96_2
Klinicheskie rekomendacii “Glaukoma pervichnaja zakrytougol’naja”. 2024. Accessed 10.12.2024 (In Russ.). https://cr.minzdrav.gov.ru/preview-cr/631_2
Alekseev IB, Ignat’ev SA, Vorob’eva IV, et al. Lechenie glaukomnoi opticheskoi neiropatii metodom endonazal’nogo elektroforeza Korteksina: uchebno-metodicheskoe posobie. Moscow: RMAPO; 2014 (In Russ.).
Trofimova SV, Maksimov IB, Neroev VV. Regulyatornoe deistvie peptidov setchatki. St. Petersburg: Foliant; 2004 (In Russ.).
Landa IV, Taskina ES, Harinceva SV. The effectiveness of Retinalamine in various ophthalmic diseases. JeNI Zabajkal’skij medicinskij vestnik. 2022;(4):98-106 (In Russ.). https://doi.org/10.52485/19986173_2022_4_98
Astahov JuS, Butin EV, Morozova NV, et al. The experience of using Retinalamine in the treatment of glaucoma neuroopticopathy and age-related macular degeneration. Oftal’mologicheskie vedomosti. 2013;5(2):45-49 (In Russ.).
Alekseev VN, Churilina NJu, Pavlova EA. Morphometric substantiation of the neuroprotective effect of peptides in primary open-angle glaucoma. Uspehi sovremennogo estestvoznanija. 2008;(2):89-91 (In Russ.).
Strahov VV, Egorov EA, Erichev VP. The effect of long-term retinoprotective therapy on the progression of glaucoma according to structural and functional studies. Russian Annals of Ophthalmology=Vestnik oftal’mologii. 2020; 136(5):58-66 (In Russ.). https://doi.org/10.17116/oftalma202013605158
Hirooka K, Kelly M, Baldridge W, et al. Suppressive actions of betaxolol on ionic currents in retinal ganglion cells may explain its neuroprotective effects. Exp Eye Res. 2000;70(5):611-621. https://doi.org/10.1006/exer.2000.0822
Osborne NN, Wood JP, Chidlow G. Invited review: Neuroprotective properties of certain beta-adrenoceptor antagonists used for the treatment of glaucoma. J Ocul Pharmacol Ther. 2005;21(3):175-181. https://doi.org/10.1089/jop.2005.21.175
Gao H, Qiao X, Cantor LB, et al. Upregulation of brain-derived neurotrophic factor expression by Brimonidine in rat retinal ganglion cells. Arch Ophthalmol. 2002;120(6):797-803. https://doi.org/10.1001/archopht.120.6.797
Krupin T, Liebmann JM, Greenfield DS, et al. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol. 2011;151(4):671-681. https://doi.org/10.1016/j.ajo.2010.09.026